In the ARCH trial, romosozumab plus alendronate outperformed alendronate alone in reducing fracture risk.

Using MRI to monitor men under active surveillance for prostate cancer may help detect measurable growth.

Anxiety and depression, often under-recognized and undertreated, may contribute to poorer outcomes.

Low proximal tibial trabecular bone mineral density may play a role in its development.